Newbiologix launches advanced rAAV platform for gene therapy production

NewBiologix, a Swiss technology innovation company specializing in cell and gene therapy production solutions, has introduced its cutting-edge Xcell rAAV Production and Analytics Platform (Xcell rAAV Platform). This platform is designed to streamline the production of recombinant adeno-associated virus (rAAV) candidates, enabling gene therapy developers to identify and manufacture optimal vectors for preclinical and clinical applications efficiently.

Leveraging its proprietary Xcell Eng-HEK293 cell line, NewBiologix offers an end-to-end solution that enhances rAAV production quality while addressing the challenges of scalability and cost-effectiveness in gene therapy development.

advancing gene therapy with xcell rAAV platform

The Xcell rAAV Platform covers the entire production process, from DNA synthesis to the manufacturing of rAAV particles. It allows gene therapy companies to screen multiple rAAV candidates in parallel, accelerating the identification of optimal therapeutic vectors while minimizing production risks. The platform also includes comprehensive data reporting to ensure compliance with regulatory standards, thereby supporting the development and clinical translation of gene therapies.

Dr. Igor Fisch, Chief Executive Officer of NewBiologix, emphasized the company’s mission to improve the efficiency of gene therapy production. He stated that the Xcell rAAV Platform reduces production timelines while delivering higher quality, enabling gene therapy developers to progress more confidently toward clinical trials.

key features of the xcell rAAV platform

Central to the platform is the Xcell Eng-HEK293 cell line, a precision-engineered tool for high-quality rAAV production. The cell line features complete genomic characterization and has been optimized for transient transfection, enhancing the efficiency and consistency of rAAV manufacturing.

Another standout capability is the platform’s ability to characterize encapsidated rAAV DNA. This includes determining the ratio of full to empty capsids, assessing the integrity of therapeutic gene sequences, and quantifying contaminant DNA—critical quality attributes for regulatory approval and clinical success.

Dr. Déborah Ley, Chief Operating Officer at NewBiologix, noted that this level of insight empowers clients to make data-driven decisions, ensuring safer and more effective gene therapies.

shaping the future of gene therapy

NewBiologix is redefining the landscape of cell and gene therapy production through its integrated platforms and expertise in cell line engineering. By addressing the limitations of traditional rAAV production processes, the company aims to accelerate the development of safer and more scalable gene therapies.

The Xcell rAAV Platform represents a significant step forward in reducing the complexity and costs associated with gene therapy development, enabling faster delivery of innovative treatments to patients.